Dolutegravir
Spezifikationen
1051375-16-6CAS-Nummer
809-888-1EG-Nummer
(3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamideIUPAC-Name
C20H19F2N3O5Chemische Formel
419.4 g/molMolekulargewicht
Dolutegravir; 1051375-16-6; GSK1349572; S/GSK1349572; GSK 1349572; GSK-1349572; S-349572; (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; DKO1W9H7M1; CHEBI:76010; DTXSID90909356; 2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide, N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-; dolutegravirum; (4R,12aS)-N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide; (4R,12aS)-N-((2,4-difluorophenyl)methyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido(5,6)pyrazino(2,6-b)(1,3)oxazine-9-carboxamide; (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[5,6]pyrazino[2,6-b][1,3]oxazine-9-carboxamide; RefChem:56964; J05AX12; DTXCID701338419; (14C)-(4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-(1,3)oxazino(3,2-a)pyrido(1,2-d)pyrazine-9-carboxamide; (4R,9aS)-5-hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid-2,4 difluorobenzylamide; 2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide, N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS); Tivicay; Dolutegravir (GSK1349572); (4r,12as)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2h-Pyrido[1',2':4,5]pyrazino[2,1-B][1,3]oxazine-9-Carboxamide; Dolutegravir DTG; Dolutegravir [USAN]; (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide; Dolutegravir (USAN); GSK1349572A; Tivicay (TN); Dolutegravir (0.1 mg/mL in Methanol); Dolutegravir [USAN:INN]; UNII-DKO1W9H7M1; Soltegravir; Dolutegravir?; HSDB 8152; C20H19F2N3O5; MFCD20488027; S-GSK1349572; 1051375-16-6 (free); 3s3m; 3s3n; 3s3o; Dolutegravir (Standard); (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[[?]:[?]]pyrazino[[?]][1,3]oxazine-9-carboxamide; DOLUTEGRAVIR [MI]; DOLUTEGRAVIR [INN]; DOLUTEGRAVIR [VANDF]; SCHEMBL82071; MLS006011137; DOLUTEGRAVIR [WHO-DD]; GTPL7365; orb1300988; orb3141325; CHEMBL1229211; SCHEMBL15397915; SCHEMBL29357473; RHWKPHLQXYSBKR-BMIGLBTASA-N; GLXC-90267; EX-A1695; BDBM50062551; EBC-27030; HY-13238R; s2667; AKOS025396657; S/GSK-1349572; CCG-268876; CS-0454; DB08930; FD43372; NCGC00346629-01; NCGC00346629-02; NCGC00346629-06; NCGC00346629-11; (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0^{3,8}]tetradeca-10,13-diene-13-carboxamide; AC-28371; AS-75277; HY-13238; SMR004702915; NS00099377; T6198; S/GSK1349572,GSK1349572; D10066; EN300-7409916; F799806; Q937224; Z2235801952; (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0(3),?]tetradeca-10,13-diene-13-carboxamide; (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0,3,8]tetradeca-10,13-diene-13-carboxamide; (4R,12.ALPHA.S)-N-((2,4-DIFLUOROPHENYL)METHYL)-7-HYDROXY-4-METHYL-6,8-DIOXO-3,4,6,8,12,12.ALPHA.-HEXAHYDRO-2H-PYRIDO(1',2':4,5)PYRAZINO(2,1-.BETA.)(1,3)OXAZINE-9-CARBOXAMIDE; (4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-a]pyrido[1,2-d]pyrazine-9-carboxamide; (4R,12aS)-N-(2,4-Difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-9-carboxamide; (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamideSynonyme
Produkte, die Dolutegravir enthalten
AcriptegaDolutegravir 50mg, Lamivudine 300mg & Tenofovir Disoproxil Fumarate 300mg TabletsDolatevirDolvir TLDHetegravir 50TRIPLEVIRGSK 1349572DolutegravirdolutegravirDolutegravirDOLUTEGRAVIRDolutegravir
Seite 1 von 2
Unternehmen, die Dolutegravir verkaufen
MP
Macleods Pharmaceuticals LimitedIndiaHD
Hangzhou Dingyan Chem Co., LtdChinaZE
Zhejiang Eazy Pharmchem Co., Ltd.ChinaCS
China Synchem Technology Co., Ltd.ChinaWH
Wuxi Hexia Chemical CompanyChinaSR
Suzhou Ryway Biotech Co., LtdChinaMP
MI Pharma Private LimitedIndiaSH
Shenzhen Haorui Pharmatech Co., Ltd.ChinaSeite 1 von 2